Gary E. Aspnes

Publications by Year

Research Areas

Pancreatic function and diabetes, Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography

Most-Cited Works

• → Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus(2011)115 cited
• → Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design(2009)107 cited
• → Regioselective Synthesis of 2H-Indazoles Using a Mild, One-Pot Condensation–Cadogan Reductive Cyclization(2014)107 cited
• → A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification(2014)87 cited
• → Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)(2015)81 cited
• → Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)(2015)68 cited
• → Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus(2011)68 cited
• → Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure–activity relationships and strategies for the elimination of reactive metabolite formation(2008)51 cited
• → The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of Type 2 diabetes mellitus(2012)44 cited
• → Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents(2018)43 cited